UBS Group’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-178,371
| Closed | -$8.53M | – | 11165 |
|
|
2025
Q3 | $8.53M | Sell |
178,371
-51,029
| -22% | -$1.42M | ﹤0.01% | 3482 |
|
|
2025
Q2 | $3.67M | Buy |
229,400
+5,717
| +3% | +$92.6K | ﹤0.01% | 4193 |
|
|
2025
Q1 | $3.4M | Buy |
223,683
+34,452
| +18% | +$552K | ﹤0.01% | 4188 |
|
|
2024
Q4 | $3.84M | Buy |
189,231
+177,385
| +1,497% | +$4.47M | ﹤0.01% | 4111 |
|
|
2024
Q3 | $305K | Buy |
11,846
+2,146
| +22% | +$35.8K | ﹤0.01% | 5558 |
|
|
2024
Q2 | $125K | Buy |
9,700
+6,879
| +244% | +$111K | ﹤0.01% | 6017 |
|
|
2024
Q1 | $64.6K | Buy |
+2,821
| New | +$99.5K | ﹤0.01% | 6398 |
|
|
2023
Q4 | – | Sell |
-14
| Closed | -$391 | – | 9894 |
|
|
2023
Q3 | $391 | Buy |
+14
| New | +$410 | ﹤0.01% | 8524 |
|
|
2023
Q2 | – | Sell |
-778
| Closed | -$14.6K | – | 9664 |
|
|
2023
Q1 | $14.6K | Sell |
778
-331
| -30% | -$5.46K | ﹤0.01% | 7334 |
|
|
2022
Q4 | $11.3K | Buy |
+1,109
| New | +$17.8K | ﹤0.01% | 8411 |
|
|
2022
Q3 | – | Sell |
-83
| Closed | -$4K | – | 10935 |
|
|
2022
Q2 | $4K | Buy |
+83
| New | +$6.55K | ﹤0.01% | 9139 |
|
|
2022
Q1 | – | Sell |
-811
| Closed | -$124K | – | 10911 |
|
|
2021
Q4 | $124K | Buy |
811
+76
| +10% | +$11.2K | ﹤0.01% | 6107 |
|
|
2021
Q3 | $100K | Buy |
735
+166
| +29% | +$22.7K | ﹤0.01% | 5833 |
|
|
2021
Q2 | $84K | Buy |
+569
| New | +$87.2K | ﹤0.01% | 6020 |
|
UBS Group's TRML Position: Q4 2025 in Review
UBS Group sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 178,371 shares — an estimated $8.53M sold.
UBS Group first reported a position in TRML in Q2 2021 and held it in 14 quarters. The position peaked at $8.53M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- UBS Group reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 178,371 Tourmaline Bio shares in Q4 2025, an estimated $8.53M.
- UBS Group first reported a position in Tourmaline Bio in Q2 2021 and held it in 14 quarters.
- UBS Group's Tourmaline Bio position peaked at $8.53M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.